Answers are grounded in this paper and cite their sources.
Despite extensive soliciting of AEs for ESK with the US Risk Evaluation and Mitigation Strategy program, respiratory depression is infrequently observed with ESK treatment in the postmarketing setting (estimated incidence: 1 case per 20 000 treatment sessions). Symptoms are manageable and resolve with minor supportive measures. Monitoring for symptoms of respiratory depression, including pulse oximetry, is recommended within the postdose observation period.
No takes yet. Share an insight, caveat, or question.
Chepke et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: